8:32 AM ET
8-K
Other 8-K Filing
Biomarin Pharmaceutical Other 8-K Filing
BioMarin Pharmaceutical Inc. announced its decision to discontinue the clinical development of VOXZOGO for children with Noonan syndrome. The company cited study feasibility and the current treatment landscape as reasons for the move, noting the decision was not related to safety or efficacy.